VEGF165 and bFGF protein-based therapy in a slow release system to improve angiogenesis in a bioartificial dermal substitute in vitro and in vivo.

Autor: Wilcke, I., Lohmeyer, J. A., Liu, S., Condurache, A., Krüger, S., Mailänder, P., Machens, H. G.
Předmět:
Zdroj: Langenbeck's Archives of Surgery; Jul2007, Vol. 392 Issue 3, p305-314, 10p, 5 Color Photographs, 1 Chart, 2 Graphs
Abstrakt: Angiogenesis can be enhanced by several growth factors, like vascular endothelial growth factor-165 (VEGF165) and basic fibroblast growth factor (bFGF). Delayed release of such growth factors could be provided by incorporation of growth factors in fibrin matrices. In this study, we present a slow release system for VEGF165 and bFGF in fibrin sealant. In vitro: Pieces of Integra™ matrix of 15 mm in diameter were prepared. Integra™ matrices were divided into four groups (A=control; B=fibrin sealant; C=fibrin sealant+growth factors; D=growth factors). In vivo: The bioartificial dermal templates were transplanted into a full-skin defect of the back of nu–nu mice. Four different groups included each six matrices at 2 and 4 weeks. In vitro: In groups C and D, continuous release of VEGF165 and bFGF was eminent. The incorporation of growth factors into fibrin sealant evoked a prolonged growth factor release ( p < 0.05). In vivo: A significantly higher amount of vessels was quantified in groups C and D compared to groups A and B ( p < 0.001). A model of slow protein release by combining VEGF165 and bFGF with fibrin sealant was produced. This model resulted in a prolonged bioavailability of growth factors in vivo for functional purposes. Fibrin and collagen can release growth factors in vivo and induce significant and faster neovascularisation in bioartificial dermal templates. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: